Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manjunath Raju

Interventional Cardiology Winter Park, FL Medical Doctor

NPI 1528251618 CMS profile 159504

1605 W Fairbanks Ave, Winter Park, FL 32789

Open in the dashboard

General payments

$32,924

575 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manjunath Raju of Winter Park, FL is reported in the CMS Open Payments database as having received $32,924 across 575 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,836 101
2024 General $6,987 148
2023 General $4,331 89
2022 General $865 44
2021 General $1,088 53
2020 General $3,981 56
2019 General $7,836 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manjunath Raju
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Manjunath Raju were reported at $7,836. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Manjunath Raju Interventional Cardiology median Middle half National median
2019 $7,836 $1,097 $329–$3,048 $163
2020 $3,981 $473 $161–$1,480 $114
2021 $1,088 $677 $233–$1,827 $132
2022 $865 $978 $333–$2,724 $149
2023 $4,331 $1,136 $382–$2,986 $160
2024 $6,987 $1,181 $395–$3,326 $164
2025 $7,836 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,890 51 payments
  2. Boston Scientific Corporation $4,705 155 payments
  3. Penumbra, Inc. $4,643 21 payments
  4. Cook Incorporated $4,500 3 payments
  5. Abbott Laboratories $3,727 31 payments
  6. Philips Electronics North America Corporation $2,591 76 payments
  7. W. L. Gore & Associates, Inc. $2,515 29 payments
  8. Abiomed $1,493 51 payments
  9. Shockwave Medical, Inc $1,260 63 payments
  10. Medtronic Vascular, Inc. $1,203 36 payments
  11. Other $1,396 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,024 521 payments
  2. Travel and Lodging $13,255 48 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,500 3 payments
  4. Consulting Fee $118 1 payment
  5. Grant $27 2 payments
Products named General payments · program years 2019–2025
  1. Indigo System $4,520 19 payments
  2. Cook Medical Zilver PTX $3,116 8 payments
  3. ENDURANT IIS $1,743 17 payments
  4. Omnilink Elite vascular stent system $1,709 9 payments
  5. GORE VIABAHN VBX Balloon Expandable Endo $1,630 13 payments
  6. WATCHMAN $1,501 19 payments
  7. Cook Medical Accessories $1,500 1 payment
  8. VENASEAL $1,467 10 payments
  9. SUPERA $1,312 8 payments
  10. IGT D Peripheral $1,283 2 payments
  11. Other $12,512 446 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,602

Median for Interventional Cardiology: 2,236

Drug cost

$314,438

Median for Interventional Cardiology: $380,412

Branded share of claims

41.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 145 $186,116
Repatha Sureclick Evolocumab Brand 59 $42,867
Entresto Sacubitril/Valsartan Brand 34 $38,408
Xarelto Rivaroxaban Brand 20 $28,799
Clopidogrel Clopidogrel Bisulfate Brand 295 $3,950
Metoprolol Succinate Generic 178 $2,190
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 95 $1,832
Atorvastatin Calcium Generic 116 $1,830
Cilostazol Generic 47 $1,378
Ranolazine Er Ranolazine Brand 12 $871

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$151,628

Medicare's payments for the services billed

Medicare patients

2,247

Average age 75

Services billed

4,048

1,140 women, 1,107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 38%
Atrial fibrillation 37%
Heart failure 36%
Chronic kidney disease 36%
Diabetes 30%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record